{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020699","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.095367+00:00","generated_at":"2026-06-22T19:00:59.316256+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pyxis Oncology Q3 net loss $27.7M, expands Pfizer ADC licensing deal","bullets":["Net loss of $27.7M ($0.85 per share) for Q3 2022 vs. $14.2M ($8.96 per share) in Q3 2021.","Cash and cash equivalents (incl. restricted) $200.0M as of Sept 30, 2022; expected to fund operations into end of 2024.","Expanded worldwide licensing deal with Pfizer for exclusive rights to Pfizer’s ADC technology platform and toolkit.","First multi-target sublicensing agreement executed with a stealth ADC company under the new Pfizer arrangement.","IND filings for PYX-106 and PYX-201 on track by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020699","json":"https://secwatch.observer/filing/0000950170-22-020699.json","markdown":"https://secwatch.observer/filing/0000950170-22-020699.md","text":"https://secwatch.observer/filing/0000950170-22-020699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/0000950170-22-020699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/pyxs-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T19:00:59.316256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0411b44e932611e409af6c8869b4e75e4809d695","claim":"Pyxis Oncology, Inc. reported three months ended September 30, 2022 results: net income $27.7 million, EPS $(0.85) per common share.","evidence_excerpt":"Net loss was $27.7 million, or $(0.85) per common share, for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/0000950170-22-020699-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"$27.7 million"},{"label":"EPS","value":"$(0.85) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}